Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2019
Headcount
6
HQ
Mazkeret Batya, Israel
Sector
Health Tech & Life Sciences
About
Quintrigen is developing p53, a targeted anti-cancer and tumor suppressor drug. The company has identified a family of small peptides that can reeducate mutant p53 to do its job. In pre-clinical models, these peptides have been shown to reactivate a wide variety of different mutant p53 proteins by refolding the mutant p53 to its natural native conformation and restoring its potent wild-type functionality, including the capability to induce cancer cell death. The treatment is shown to be highly selective against cancer cells, sparing normal cells and tissues. Quintrigen is a joint venture of the Weizmann institute in Israel and South Korean biotech Bioleaders.
Q&A
- What is Quintrigen's primary focus?
- Quintrigen is developing p53, a targeted anti-cancer and tumor suppressor drug.
- What is the status of Quintrigen?
- Quintrigen is currently inactive and ceased to operate in July 2025.
- When was Quintrigen founded?
- Quintrigen was founded in May 2019.
- What is Quintrigen's employee count?
- Quintrigen has 1-10 employees.
- Who are the founders of Quintrigen?
- The founders of Quintrigen are Orna Palgi, who serves as CEO, and Anat Nursella, who serves as CFO.
- What is the core technology behind Quintrigen's drug development?
- Quintrigen has identified small peptides that can reactivate mutant p53 proteins by refolding them to their natural conformation, restoring their wild-type functionality to induce cancer cell death.
- What is the selectivity of Quintrigen's treatment?
- The treatment developed by Quintrigen is shown to be highly selective against cancer cells, while sparing normal cells and tissues.
- What is Quintrigen's current funding stage?
- Quintrigen is currently in the Pre-Funding stage.
- What is the nature of Quintrigen's collaboration?
- Quintrigen is a joint venture between the Weizmann Institute in Israel and the South Korean biotech company Bioleaders.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
peptidesdrug-discoverypharmaceuticalscancerbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019-5 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Jul 2025 ceased to operate |